Renalytix to Present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Rhea-AI Summary

Renalytix plc (NASDAQ: RNLX) announced its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostics Tools Conference set for February 15, 2022, at 3:30 p.m. EST. The event will feature a fireside chat, but it will not be webcast. Investors can register for virtual one-on-one meetings. Renalytix is a pioneer in bioprognosis for kidney health, with its key product, KidneyIntelX, receiving Breakthrough Designation from the FDA. This innovative solution aims to enhance kidney disease management and patient care.

NEW YORK and SALT LAKE CITY, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (“Renalytix” or the “Company”) today announced the Company will be presenting at the upcoming BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference.

Renalytix’s management is scheduled to participate in a fireside chat on Tuesday, February 15, 2022, at 3:30 p.m. EST. Due to the format of this virtual event the presentation will not be webcast. The company will be available for virtual 1X1 meetings with investors registered for the event.

About Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is the global founder and leader in the new field of bioprognosis™ for kidney health. The company has engineered a new solution that successfully enables early-stage CKD progression risk assessment. The Company’s lead product, KidneyIntelX, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.

For further information, please contact:

Renalytix plc			www.renalytix.com
James McCullough, CEO			Via Walbrook PR
Stifel (Nominated Adviser, Joint Broker)			Tel: 020 7710 7600
Alex Price / Nicholas Moore
Investec Bank plc (Joint Broker)			Tel: 020 7597 4000
Gary Clarence / Daniel Adams
Walbrook PR Limited	Tel: 020 7933 8780 or renalytix@walbrookpr.com
Paul McManus / Lianne Applegarth		Mob: 07980 541 893 / 07584 391 303
CapComm Partners
Peter DeNardo			Tel: 415-389-6400 or investors@renalytix.com

FAQ

What is the date of Renalytix's presentation at the BTIG Conference?

Renalytix will present at the BTIG MedTech Conference on February 15, 2022.

What time will Renalytix's management participate in the fireside chat?

The fireside chat is scheduled for 3:30 p.m. EST.

Will Renalytix's presentation be available for webcast?

No, the presentation will not be webcast due to the virtual event format.

What is KidneyIntelX and its significance for Renalytix?

KidneyIntelX is Renalytix's lead product, designed for early-stage chronic kidney disease risk assessment, and has received Breakthrough Designation from the FDA.

How can investors meet with Renalytix at the conference?

Investors can register for virtual one-on-one meetings with Renalytix's team during the event.